Background: Pompe disease is a rare lysosomal glycogen storage disorder linked to the acid alpha-glucosidase
Data supporting the selection were presented at the 14th Annual WORLDSymposium 2018 in a poster titled: "A Novel Hybrid Promoter Directing AAV-mediated Expression of Acid Alpha-Glucosidase
to Liver, Muscle, and CNS Yields Optimized Outcomes in a Mouse Model of Pompe Disease.
Biotechnology company Audentes Therapeutics Inc (Nasdaq:BOLD) stated on Tuesday that the data supporting the selection of optimized clinical development candidate were presented at the 14th Annual WORLDSymposium 2018 in Poster #123, titled: "A Novel Hybrid Promoter Directing AAV-mediated Expression of Acid Alpha-Glucosidase
to Liver, Muscle and CNS Yields Optimized Outcomes in a Mouse Model of Pompe Disease.
In another study, we actually find that salacia is a more potent glucose inhibitor than acarbose, a commercial alpha-glucosidase
inhibitor found in diabetic medications.
We found statistically significant correlations between increased resistance to 5-fluorocytosine and higher activity of naphthyl phosphohydrolase and lipase; increased resistance to miconazole and higher activity of beta-glucosidase; increased resistance to fluconazole and higher activity of alpha-glucosidase
, alpha-galactosidase, and fucosidase.
In patients with type 1 diabetes, insulin is used, whereas in patients with type 2 diabetes, sulfonylurea, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, alpha-glucosidase
inhibitors, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used.
Antisense Oligonucleotide to Activate Acid Alpha-Glucosidase
for Pompe Disease - Drug Profile 41
There are seven pharmacologic subclasses of oral antidiabetic agents: alpha-glucosidase
inhibitors, biguanides, dipeptidyl peptidase-4 inhibitors, meglitinides, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and thiazolidinediones.
Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase
and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice.
The greatest compliance was observed with alpha-glucosidase
inhibitors (100%) and meglitinides (100%); nonetheless, only 5 participants used these drugs.
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy Metformin, Alpha-Glucosidase
Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.